Catalyst
Monitor results from the Phase I trial, particularly the effectiveness of the iontophoresis delivery method and subsequent studies on larger populations.
Humanexa recommends Monitor.
Date
July 20, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.